Hutton, who joined the ASCB in 1997, was born in Australia. He earned a BSc in Biochemistry and Physiology in 1969 and his PhD in 1974 at the University of New South Wales. After postdocs in Bolivia and Belgium, Hutton established his own laboratory in the Department of Clinical Biochemistry at the University of Cambridge, UK, where he investigated the physical and molecular properties of the insulin secretory granule and its role in diabetes pathogenesis.
He came to the United States in 1995 as Research Director at the Barbara Davis Center where he also made seminal contributions to our understanding of islet autoimmunity, including the identification of two proteins (IA2-ß aka phogrin and IGRP) that were subsequently shown to be molecular targets of human auto reactive T cells.
Most recently, Hutton demonstrated that the granule protein ZnT8 is a major target of both human T cells and autoantibodies, a discovery that has been called the most significant advance in the development of biomarkers for type 1 diabetes for over a decade.
The Davis Center is holding an all-day "John C. Hutton Science Symposium," April 12, at the University of Colorado, Anschutz Medical Campus.